Navigation Links
GlaxoSmithKline Completes Acquisition of Stiefel
Date:7/22/2009

RESEARCH TRIANGLE PARK, N.C., July 22 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (GSK) (NYSE: GSK) today announced that it has completed its acquisition of Stiefel Laboratories, Inc. GSK has acquired the total share capital of Stiefel for a cash consideration of $2.9 billion. GSK also assumed $0.4 billion of net debt. Under the terms of the agreement, GSK may be obligated to make additional cash payments of up to $0.3 billion depending on the future performance of the business. The new dermatology business unit within GSK will operate under the name Stiefel, a GSK company.

Deirdre Connelly, President, North American Pharmaceuticals, GSK said, "The Stiefel acquisition demonstrates how we are implementing our strategy to grow and diversify our business through targeted acquisitions. We now have established a new world-leading, specialist dermatology business that will immediately generate new revenue flows to GSK."

Charles Stiefel, Chairman of Stiefel, said, "As part of GSK, we are stronger, more competitive and continue to be a driving force in dermatology around the world. We are excited to combine GSK's prescription dermatology products, such as Bactroban, Cutivate and Altabax, with Stiefel's portfolio, including brands such as Duac, Olux E and Soriatane. This combined portfolio, together with our specialty sales force and GSK's global presence, positions GSK's dermatology business for significant growth."

Sales of Stiefel's products for 2008 were approximately $900 million and sales of GSK's prescription dermatology products were approximately $550 million. The combined pro forma revenues of approximately $1.5 billion, represent an 8% share of the glo
'/>"/>

SOURCE GlaxoSmithKline plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
2. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
3. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
4. GlaxoSmithKline Reports Q4 and Year End Results 2008
5. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
6. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
7. AUDIO from Medialink and GlaxoSmithKline: FDA Approves Boostrix for Adults
8. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
9. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
10. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
11. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield ... skin while battling the weakening threat of inflammaging, ... is formulated with star ingredient GLYCOSEA, a complex ... a complex of soothing minerals and trace elements. ...
(Date:4/30/2015)... Kent, WA (PRWEB) April 30, 2015 ... recently developed ultrafiltration membranes, the PX, PY, ... test coupons, sheets, and disks. Designed to ... applications, these new membranes can fill critical process ... effluent hinder downstream processes. , “New regulations on ...
(Date:4/29/2015)... GUELPH, ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... twelve-month periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , ... 1,191 , 1,493 , 3,377 , ...
(Date:4/29/2015)... 29, 2015 AlloSource ®, one ... bone, skin and soft-tissue allografts for use in ... healing, announced the launch of AlloSkin™ AC, an ... Medicaid Services (CMS) also moved AlloSkin™ RT, a ... the high-cost category for reimbursement. "AlloSource ...
Breaking Biology Technology:Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Sterlitech Offers New Ultrafiltration Membranes 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4AlloSource Announces New Possibilities In Wound Care 2
... Entrepreneur Anthony ... Directors, IRVINE, Calif., Sept. 5 NeoMatrix, developer of ... to,identify breast cancer risk, announced today that the company has ... enable an expanded,market release of the HALO System, which is ...
... Sept. 5 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) ... the Bear Stearns 20th Annual Healthcare Conference on September,11, ... Time) at the Grand,Hyatt Hotel in New York City. ... to provide a corporate overview of the,company and its ...
... the Key Problems Faced by Insomniacs, i.e.,Sleep Onset and ... Today at 11:00 am CET (10:00 am UK,time, 5:00 ... Congress in,Australia HAMBURG, Germany and OXFORD, England, September ... the worldsleep07 congress in Cairns, Australia the,details of the ...
Cached Biology Technology:NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 2NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 3NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 4Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 2Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 4
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch ... of MDC and Charit in Berlin-Buch have gained ... and their molecular repertoire. Dr. Max Werth, Katharina ... transcription factor (grainyhead-like 2, Grhl2), which regulates the ...
... PhD student are part of a research team that ... oxygen levels in the oceans high enough to establish ... By examining ancient-ocean sediments, Kurt Konhauser, student ... last glacier to encircle Earth receded, leaving behind glacial ...
... DURHAM, N.H. A major new study that sounds ... the world,s seagrass species are faring somewhat better, says a ... the study. Fred Short, UNH research professor ... was among the 174 scientists who contributed to "The Impact ...
Cached Biology News:New insights into the development of epithelial cells 2UNH's Fred Short adds seagrass data to major conservation study 2
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
... assay (EMSA) is a powerful tool for ... gel shift or gel retardation, the assay ... subjected to electrophoresis, free DNA will migrate ... LightShift Chemiluminescent EMSA Kit is a nonradioactive ...
... The Guava PCA-96 systems provide automated, ... a tray of microcentrifuge tubes. This flexible ... ideal for screening in basic research, target ... Like it's smaller cousin, the Guava PCA-96 ...
... Cellomics KineticScan™ Reader is Cellomics‘ ... Solutions for Cell-based Screening". The ... ability to do both temporal ... physiological processes, dynamic distribution and ...
Biology Products: